**Core tip:** Gastro-jejunal (GJ) anastomotic stricture is a common late complication of Roux-en-y gastric bypass. Pneumatic dilation is the first line treatment for these strictures and fully covered self-expanding metal stent (fcSEMS) can be used as an alternative. In this case report we represent the successful off-label placement of lumen apposing metal stent instead of fcSEMS for GJ anastomotic stricture.

INTRODUCTION
============

Worldwide obesity has tripled since 1975. The number of bariatric surgeries performed each year in united states has been increasing steadily with approximately 196000 surgeries performed in the year 2015\[[@B1]\]. Roux-en-y gastric bypass (RYGB) is the second most common bariatric surgery performed after sleeve gastrectomy. One of the late complications of this procedure is gastro-jejunal (GJ) anastomotic stricture\[[@B2]\]. Initially this is typically managed safely with pneumatic dilation\[[@B3]\]. Alternatives to dilation include needle-knife incisional therapy, local steroid injection and fully covered self-expanding metal stent (fcSEMS). The fcSEMS has a high rate of adverse events including stent migration and recurrence of strictures after removal of stent\[[@B4]\]. Lumen apposing metal stent (LAMS) was initially used for draining pancreatic fluid collections/cystogastrostomy though recently has been used in various locations throughout the gastrointestinal tract due to its novel dumbbell shaped design. In this case report we present a case of GJ anastomotic stricture successfully managed with LAMS after failure of serial balloon dilations and steroid injections. LAMS was preferred over fcSEMS to avoid the high rate of complications.

CASE REPORT
===========

A 42-year-old female with history of RYGB performed seven years ago, complicated by GJ anastomotic ulcer three years ago was seen in follow-up for symptomatic GJ anastomotic stricture. She reported weakness, fatigue and a 50-pound weight loss over the past year due to her inability to tolerate both solids and liquids orally. Her BMI was 18.79 and she did not have any medical comorbidities including no obstructive sleep apnea or hypertension. Patient's GJ anastomotic ulcer healed two years ago after starting a hydrogen-potassium ATPase inhibitor and she reduced her smoking from one pack per day to three cigarettes per day. For her persistent GJ anastomotic stricture she underwent through-the-scope (TTS) dilation twice this year and twice in the year before with triamcinolone injected in the stricture on her second dilation. These measures provided only temporary relief of her symptoms. On her last esophagogastroduodenoscopy (EGD), she had persistent GJ stricture and no gastro-gastric fistula. Her *Helicobacter pylori* status was negative on multiple occasions on stool antigen testing and on microscopic examination of obtained tissue samples during EGD. We performed a repeat EGD on which the GJ anastomosis was characterized by severe stenosis (2 mm opening) (Figure [1](#F1){ref-type="fig"}). A LAMS (Axios stent 15 mm x 10 mm; Boston Scientific, Marlborough, MA, United States) was placed into the anastomotic stricture (Figures [2](#F2){ref-type="fig"}-[4](#F4){ref-type="fig"})[](#F2){ref-type="fig"}[](#F3){ref-type="fig"}[](#F4){ref-type="fig"}. A wire-guided TTS balloon dilator (CRE; Boston Scientific, Marlborough, MA, United States) was passed over a guidewire (Hydra Jagwire 0.035 cm x 260 cm; Boston Scientific, Marlborough, MA, United States) through the LAMS. Dilation with 10 mm-11 mm-12 mm anastomotic balloon dilators was performed and held inflated for 2 min under fluoroscopic guidance. Our patient did not develop any immediate or delayed stent-related adverse events. Patient's symptoms improved remarkably after the procedure, she had gained 5 pounds and was asymptomatic on three-month follow-up. We aim to remove the stent after a total of six months for maximum effect.

![Gastro-jejunal anastomotic stricture with 2 mm opening.](WJGE-10-117-g001){#F1}

![Axios stent placed in gastro-jejunal anastomotic stricture.](WJGE-10-117-g002){#F2}

![Dilated gastro-jejunal anastomotic stricture with visible jejunal lumen.](WJGE-10-117-g003){#F3}

![Confirmation of lumen apposing metal stent with fluoroscopic guidance.](WJGE-10-117-g004){#F4}

DISCUSSION
==========

RYGB is associated with both early and late adverse events. The early adverse events include staple/suture leak, postoperative hemorrhage and bowel obstruction. Late adverse events include but are not limited to marginal ulceration, fistula formation, nutritional deficiencies, difficulty performing endoscopic retrograde cholangiopancreatography (ERCP) and anastomotic stricture. The rate of GJ anastomotic stricture ranges between 2.9% to 23% after RYGB\[[@B5]-[@B7]\]. Factors that are implicated in development of this adverse events include anastomotic dehiscence, local ischemia, tension at anastomosis, healing capacity of patient, non-adherence to recommended nutrition and the technique used to create the anastomosis\[[@B4],[@B8],[@B9]\]. This condition is more common in patients with laparoscopic RYGB compared to an open approach\[[@B6]\]. Patients can present anywhere from a couple of weeks to months post-operatively with progressively worsening dysphagia, nausea, vomiting, gastroesophageal reflux and epigastric pain\[[@B8]\]. GJ anastomotic stricture can be identified through various radiographic studies though EGD should be performed if suspected.

Pneumatic dilation is the first line therapy for GJ anastomotic strictures and has shown good results though in some cases serial dilations may be required\[[@B6],[@B9]-[@B11]\]. Carrodeguas et al\[[@B12]\] reported a mean of two dilatory sessions required to achieve an anastomotic diameter of 10 mm to 16.5 mm for 94 patients with GJ anastomotic stricture identified through retrospective analysis. Rate of perforation in this study was reported as 2.1%. Alternatives to pneumatic dilation include needle-knife incisional therapy\[[@B13]\] and fcSEMS. The fcSEMS are not ideal due to the high rate of adverse events including intolerance, stent migration and recurrence of symptoms after stent removal\[[@B14]\]. LAMS were originally FDA approved for draining pancreatic fluid collections\[[@B15]\] but case reports/series of off-label use have been recently published with promising results. Gastrointestinal strictures/stenosis where LAMS has been successfully used include benign esophageal stricture, benign gastric outlet obstruction\[[@B16]\], malignant duodenal stricture, colorectal anastomotic stricture\[[@B17]\] and GJ anastomotic stricture\[[@B18]\]. Bazerbachi et al\[[@B19]\] published a multi-center retrospective analysis of 49 patients who underwent 56 LAMS placement procedures for benign gastrointestinal luminal strictures, 77.6% of these patients had anastomotic strictures with 34.7% (17/49) being gastro-jejunal. 36.4% LAMS placed at anastomotic strictures required re-intervention and rate of migration for upper gastrointestinal strictures was 11.1%.

In our case we describe an off-label use of LAMS for GJ anastomotic stricture as a result of RYGB. LAMS was utilized here due to stricture caused by ulceration induced stenosis and not purely "anastomotic stricture", there was fibrosis from multiple prior dilation attempts. In contrast to conventional fcSEMS, the LAMS is shorter, smaller and its novel dumbbell shape design prevents leakage and migration due to 24 mm anchoring flanges. The stent is deployed with or without fluoroscopic guidance and this is a TTS device. Using conventional stents such as fcSEMS have a higher chance of migration despite using clip fasteners with higher rate of adverse events including ulceration and perforation. The inflation of CRE balloon inside Axios stent causes shortening as with fcSEMS, however due to novel dumbbell design the risk of migration while dilating the stricture through LAMS is very low. The manufacturer recommendation on LAMS duration for cystogastrostomy is four weeks. For off-label use commonly chosen duration is three months\[[@B16],[@B17]\], we intend to keep it in for six months for maximal effect and to prevent stricture recurrence/stent replacement.

Recently published literature has suggested safety and efficacy of LAMS for management of GJ anastomotic strictures and this stent provides us with an alternative to fcSEMS. In our case LAMS was successful in controlling patient's symptoms without any adverse events. Future randomized controlled trials are warranted to compare the safety, efficacy and cost effectiveness of more expensive LAMS to conventional fcSEMS.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

Our patient's main reported symptoms were weakness, fatigue and a 50-pound weight loss.

Clinical diagnosis
------------------

On esophagogastroduodenoscopy (EGD) patient was found to have a gastro-jejunal (GJ) anastomotic stricture.

Differential diagnosis
----------------------

A careful endoscopic evaluation is necessary to exclude alternative diagnosis such as marginal ulcer and gastro-gastric fistula which can present with similar symptoms.

Laboratory diagnosis
--------------------

Main laboratory testing for GJ anastomotic stricture involves checking for *Helicobacter Pylori* through hydrogen breath test, serology, stool antigen test or microscopic examination of obtained tissue during EGD.

Imaging diagnosis
-----------------

No imaging techniques were used in diagnosis and management of this case though an upper gastrointestinal series can be performed to diagnosis GJ anastomotic stricture/stenosis.

Pathological diagnosis
----------------------

No *Helicobacter pylori* organisms were found on microscopic examination of specimens obtained during EGD.

Treatment
---------

Lumen apposing metal stent (LAMS) was deployed in GJ anastomotic stricture during EGD while patient was continued on daily proton pump inhibitor orally.

Term explanation
----------------

The term "Hydrogen-potassium ATPase inhibitor" mentioned in this case report is more commonly known as "proton pump inhibitor".

Experiences and lessons
-----------------------

The newer LAMS is a safe and effective option for management of GJ anastomotic stricture and provides us with an alternative to fully covered self-expanding metal stent.
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